| Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. | |
| | |
MedLine Citation:
|
PMID: 18315581 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Although the aetiology of globus (the sensation of a lump in the throat) remains unclear, gastro-oesophageal reflux disease is associated with globus. A short-term trial with a high-dose proton pump inhibitor has been shown to be a sensitive tool for diagnosing gastro-oesophageal reflux disease. AIM: To see whether patients with globus symptom responded to short-term high-dose rabeprazole trial and assess predictors of symptom response. METHODS: Sixty-four patients with globus symptom were analysed. Patients received rabeprazole 20 mg b.d. for 14 days. Patients completed a daily diary assessing the severity and frequency of globus. RESULTS: Forty-one patients (64%) were diagnosed clinically with gastro-oesophageal reflux disease. Based on the pH testing and endoscopy, the prevalence of gastro-oesophageal reflux disease was 22% (14 of 64). The globus symptom score was significantly higher in patients with gastro-oesophageal reflux disease compared with patients without gastro-oesophageal reflux disease (P = 0.004). Two patients (3%) had complete resolution and 22 (34%) had more than a 50% improvement in the globus symptom score. Endoscopic findings (P = 0.714), pathological acid exposure on pH testing (P = 0.741) or baseline gastro-oesophageal reflux disease symptoms (P = 0.606) were not associated with improvement of globus symptom. CONCLUSION: While gastro-oesophageal reflux disease may be an aggravating factor in patients with globus, it does not appear to be the sole cause of globus symptom. |
| | |
Authors:
|
D H Sinn; J H Kim; S Kim; H J Son; J J Kim; J C Rhee; P-L Rhee |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2008-02-27 |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 27 ISSN: 1365-2036 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-05-20 Completed Date: 2008-08-01 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1275-81 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles
/
administration & dosage* Anti-Ulcer Agents / administration & dosage* Dose-Response Relationship, Drug Drug Administration Schedule Female Gastroesophageal Reflux / drug therapy* Humans Male Middle Aged Predictive Value of Tests |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 32828355LL/rabeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study...
Next Document: Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibito...